Kiernan Colleen M, Lee Jeffrey E
Department of Surgical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Department of Surgical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Surg Oncol Clin N Am. 2019 Apr;28(2):309-326. doi: 10.1016/j.soc.2018.11.011. Epub 2019 Jan 11.
Since the first description of laparoscopic adrenalectomy (LA) for pheochromocytoma and Cushing syndrome in 1992, the utilization of and indications for a minimally invasive approach to the adrenal gland have vastly expanded. Although minimally invasive adrenalectomy has been established as the preferred approach for patients with benign tumors of the adrenal gland, minimally invasive adrenalectomy for cancer remains controversial. In this article, the authors review the indications for minimally invasive adrenalectomy for adrenal nodules suspicious for, or established to represent, a primary malignancy or a site of metastatic cancer.
自1992年首次描述用于嗜铬细胞瘤和库欣综合征的腹腔镜肾上腺切除术（LA）以来，肾上腺微创方法的应用和适应证已大幅扩展。尽管微创肾上腺切除术已被确立为肾上腺良性肿瘤患者的首选方法，但肾上腺癌的微创肾上腺切除术仍存在争议。在本文中，作者回顾了对疑似或已确定为原发性恶性肿瘤或转移癌部位的肾上腺结节进行微创肾上腺切除术的适应证。
